Página 1 dos resultados de 13809 itens digitais encontrados em 0.215 segundos

Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15

CARVALHO, Luciana V.; RUIZ, Rita de C.; SCARAMUZZI, Karina; MARENGO, Eliana B.; MATOS, Jivaldo R.; TAMBOURGI, Denise V.; Fantini, Marcia Carvalho de Abreu; SANT`ANNA, Osvaldo A.
Fonte: ELSEVIER SCI LTD Publicador: ELSEVIER SCI LTD
Tipo: Artigo de Revista Científica
ENG
Relevância na Pesquisa
36.711572%
In 2006, the first report of a nanostructured material as adjuvant was described establishing the effectiveness of the ordered mesoporous SBA-15 silica as an immune adjuvant. The present study evaluated the SBA-15 capacity to modulate the immune responsiveness of High and Low responder mice immunized with BSA encapsulated/adsorbed in SBA-15 by the intramuscular or oral route and the adjuvant effect was compared with the responsiveness induced by BSA in aluminum hydroxide salts or emulsified in Incomplete Freund adjuvant. These results demonstrate the ability of the non-toxic SBA-15 nanoparticles to increase the immunogenicity and repair the responsiveness of the constitutively low responder individuals inducing both the IgG2a and the IgG1 isotypes, independently of the immune cell committed and conditioning the low phenotype. This new adjuvant may reveal novel therapeutic targets for immune modulation and vaccine design. (C) 2010 Elsevier Ltd. All rights reserved.; Conselho Nacional de Pesquisa, Brazil [CNPq]; Conselho Nacional de Pesquisa, Brazil; Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil [FAPESP]; Cristalia Pharmaceutics; Cristalia Pharmaceutics

Oportunidades, demanda regulatória e de pesquisa e uso de adjuvantes siliconados na agricultura; Opportunities, regulatory and research demand and silicone adjuvant use on agriculture

Veronese, Rogério
Fonte: Biblioteca Digitais de Teses e Dissertações da USP Publicador: Biblioteca Digitais de Teses e Dissertações da USP
Tipo: Dissertação de Mestrado Formato: application/pdf
Publicado em 23/04/2015 PT
Relevância na Pesquisa
36.711572%
Atualmente, o mercado no Brasil de adjuvantes é de aproximadamente 400 milhões de dólares, sendo que a maior parte são os óleos, o que demonstra o pouco conhecimento sobre o uso de adjuvante organossiliconado. Foi realizada extensa revisão de literatura na Internet, Associações, Empresas privadas, bem como opinião de Especialistas. Pode-se concluir que os organossiliconados podem ser usados para herbicidas, fungicidas, inseticidas, reguladores vegetais, fertilizantes foliares e biopesticidas, devido às características toxicológicas e ambientais favoráveis, bem como os benefícios de melhoria da ação dos produtos, destacando-se a melhor performance em termos de penetração, absorção, retenção e cobertura de ingrediente ativo devido ao conceito de fluidez estomatal e penetração cuticular, que pode permitir redução do volume de água evitando a perda por escorrimento e permitindo melhor eficiência no manejo de problemas fitossanitários. Os adjuvantes organossiliconados não são iguais. Para se obter melhores resultados, é importante considerar: (i) as condições ambientais, (ii) as espécies vegetais, (iii) os sistemas de aplicação, (iv) o sistema de cultivo como um todo, (iv) os ingredientes ativos e (v) o alvo. A criação de uma regulamentação clara e simples é necessária...

Estudo da relação estrutura-atividade de saponinas hemolíticas e/ou imunoadjuvantes mediante uso de análise multivariada; Study of the structure-activity relationship of adjuvant and/or hemolytic saponins by use of multivariate analysis

Kaiser, Samuel; Pavei, Cabral; Gonzales Ortega, George
Fonte: Universidade Federal do Rio Grande do Sul Publicador: Universidade Federal do Rio Grande do Sul
Tipo: Artigo de Revista Científica Formato: application/pdf
POR
Relevância na Pesquisa
36.67082%
Entre as diversas atividades biológicas relatadas para as saponinas, merecem destaque aquelas relacionadas ao aumento da resposta imune e a ruptura das membranas dos eritrócitos. No desenvolvimento de vacinas, ambas as propriedades exercem atividades antagônicas, contudo, as informações sobre as relações estrutura-atividade são relativamente escassas e, às vezes, conflitantes. O presente trabalho visa contribuir no estabelecimento das relações estruturais envolvidas com as atividades imunoadjuvante e hemolítica de saponinas triterpênicas. Para isso, foram selecionadas vinte saponinas de estrutura triterpênica, isoladas das espécies Aesculus hippocastanum, Dolichos lablab e Glycine max. A relação entre grupamentos substituintes do anel triterpênico e as atividades biológicas foi estudada mediante análise de agrupamentos e análise de componentes principais. Os resultados confirmam a importância da presença de açúcares em C-3 para a atividade hemolítica. Porém o efeito causado pela presença de uma hidroxila em C-16, de CH2OH em C-17, de uma acetila em C-22 e de um grupamento acila em C-21 sobre essa atividade parece ser mais acentuado. Já a presença de uma hidroxila em C-21, de uma metila em C-17 e de dois açúcares ligados à aglicona parece ser determinante para a atividade imunoadjuvante. Além disso...

Deposition and leaching of tebuthiuron on sugar cane straw applied with and without alkyl polyglycoside adjuvant

Negrisoli, Eduardo; Da Costa, Eduardo Antonio Drolhe; Velini, Edivaldo Domingues; Cavenaghi, Anderson Luis; Tofoli, Gustavo Radomille
Fonte: Universidade Estadual Paulista Publicador: Universidade Estadual Paulista
Tipo: Conferência ou Objeto de Conferência Formato: 207-214
ENG
Relevância na Pesquisa
36.711572%
A laboratory experiment was carried out aiming to study the effects of an alkyl polyglycoside adjuvant (APG) on deposition and leaching of the herbicide tebuthiuron applied on sugar cane straw. Tebuthiuron, at concentration of 1200 mg L-1, was applied separately and in tank mix with the APG adjuvant, at concentrations of 0.07 and 0.09% (wt v-1), using a spraying volume of 204 L ha-1. A precipitation equivalent to 20 mm of rain was simulated, 24 h after the applications, to evaluate the herbicide leaching. The quantification of tebuthiuron was carried out by the high performance liquid chromatography (HPLC). It was observed that the addition of APG adjuvant at 0.07% (wt v-1) provided an increase of 11.5% in the deposition of tebuthiuron on straw, reduction of 50.4% in the drift of the herbicide and it did not affect significantly the leached amount (68.5%), when compared with the treatment where tebuthiuron was applied alone (70.8%). At the concentration of 0.09% (wt v-1), the APG adjuvant caused an increase of 22.7% in the deposition; it reduced the drift of the herbicide by 99.9% and reduced the leached amount by 7.6% thereby increasing the retention of the herbicide by straw.

The Effect of Neo-adjuvant Platinum-based Combination Chemotherapy on Pathological Down-staging and Survival of Patients with Locally Advanced Bladder Cancer

Scosyrev, Emil ; Fisher, Susan G.
Fonte: Universidade de Rochester Publicador: Universidade de Rochester
Tipo: Tese de Doutorado
ENG
Relevância na Pesquisa
36.856467%
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Community and Preventive Medicine, 2010.; Background Bladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United States, with more than 70,000 new cases and more than 14,000 BC deaths reported in year 2009. The overwhelming majority of deaths from BC occur among patients with muscle-invasive disease (stages T2-T4). Standard therapy for resectable (T2-T4a) muscle-invasive BC without known metastases includes radical cystectomy. Unfortunately, 30%-50% of patients with apparently resectable muscle-invasive BC (“locally advanced” disease) in fact have undiagnosed micrometastases at the time of definitive surgery. Early treatment of micrometastatic disease with neo-adjuvant platinum-based combination chemotherapy (PBCC) administered before cystectomy has been compared to cystectomy alone in several randomized trials. A meta-analysis of these trials demonstrated that addition of a neo-adjuvant PBCC regimen to definitive surgery can substantially increase the probability of tumor down-staging to pathological stage zero (pT0) and improve survival. However, it is currently unknown whether PBCC is effective for all most commonly encountered histologic sub-types of BC...

Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer

Ouagari, K.; Karnon, J.; Delea, T.; Talbot, W.; Brandman, J.
Fonte: Kluwer Academic Publ Publicador: Kluwer Academic Publ
Tipo: Artigo de Revista Científica
Publicado em //2007 EN
Relevância na Pesquisa
36.67082%
Adjuvant tamoxifen therapy for 5 years reduces recurrence in hormone receptor positive, post-menopausal women with early breast cancer, but offers no advantage when prolonged to another 5 years, during which the risk of recurrence remains high. Treating patients, who remain disease-free after 5 years of tamoxifen, with letrozole significantly reduces recurrence, regardless of nodal status. This study evaluated the life-time cost-utility of extended adjuvant letrozole therapy in 62-year-old patients from a third-party payer perspective. A Markov model incorporated locoregional, contralateral, and metastatic recurrences. The comparator was placebo. Event rates were based on published trials. Utility values were taken from a clinical trial and published literature. Costs were obtained from published literature, provincial payment schedules, cancer agencies, and drug plans formularies. Resource use reflected Canadian treatment patterns. Robustness of the model was tested using deterministic and probabilistic sensitivity analyses. Extended adjuvant letrozole therapy of a cohort consisting of 50% node-negative and 50% node-positive patients prolonged their lives on average by 0.466 years or 0.267 quality-adjusted life years (QALYs) at an additional cost of Can$8...

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer

Delea, T.; Karnon, J.; Smith, R.; Johnston, S.; Brandman, J.; Sung, J.; Goss, P.
Fonte: Amer Med Publishing Publicador: Amer Med Publishing
Tipo: Artigo de Revista Científica
Publicado em //2006 EN
Relevância na Pesquisa
36.67082%
Background: MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrolment) with early breast cancer, post-5 years Methods: A Markov model was used to estimate the incremental cost per QALY gained with extended adjuvant letrozole versus no therapy. Probabilities of disease progression and death were estimated using data from the MA17 study and other secondary sources. Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature. A full probabilistic sensitivity analysis was undertaken. The analysis was conducted from the perspective of the UK National Health Service (NHS) and cost estimates reflect 2004 values. All costs and outcomes were discounted at 3.5%. Results: Extended adjuvant letrozole resulted in a gain of 0.36 QALYs per patient (13.66 vs 13.30 with no therapy). These benefits were obtained at an additional expected lifetime cost of Lstg 3732 per patient (Lstg 10 Conclusion: Five years of letrozole therapy appears to be cost effective from the NHS perspective and should be considered in women with early breast cancer...

Adjuvant 5-fluorouracil in the treatment of localised ocular surface squamous neoplasia

Rudkin, A.; Muecke, J.
Fonte: British Med Journal Publ Group Publicador: British Med Journal Publ Group
Tipo: Artigo de Revista Científica
Publicado em //2011 EN
Relevância na Pesquisa
36.67082%
Aim: To report the outcome of treatment of localised non-invasive ocular surface squamous neoplasia (OSSN) where topical 5-fluorouracil (5-FU 1%) is used as an adjuvant to surgical excision. Methods: The study was a prospective non-comparative interventional case series. 55 cases of primary localised OSSN and 10 cases of recurrent localised OSSN were treated with excision, cryotherapy and adjuvant 5-FU 1%. In all cases, irrespective of the involvement of surgical margins, a single cycle of 5-FU 1% was administered, four times a day for 2 weeks continuously. The main outcome measures were (1) recurrence and (2) complications related to adjuvant topical chemotherapy. Individuals were reviewed for a minimum of 12 months. Results: There was a single case of recurrence (1.5%). 57% of patients had short-term complications secondary to 5-FU 1%, most frequently lid toxicity (49%), followed by superficial keratitis, epiphora and corneal epithelial defects. Four patients were unable to complete the course of 5-FU 1% because of local toxicity. Conclusions: The management of localised non-invasive OSSN with adjuvant 5-FU 1% was associated with a low rate of local recurrence. Although 5-FU 1% frequently results in short-term complications, most commonly lid toxicity...

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

Burmeister, B.; Henderson, M.; Ainslie, J.; Fisher, R.; Di Iulio, J.; Smithers, B.; Hong, A.; Shannon, K.; Scolyer, R.; Carruthers, S.; Coventry, B.; Babington, S.; Duprat, J.; Hoekstra, H.; Thompson, J.
Fonte: The Lancet Publishing Group Publicador: The Lancet Publishing Group
Tipo: Artigo de Revista Científica
Publicado em //2012 EN
Relevância na Pesquisa
36.769104%
BACKGROUND: The use of radiotherapy after therapeutic lymphadenectomy for patients with melanoma at high risk of further lymph-node field and distant recurrence is controversial. Decisions for radiotherapy in this setting are made on the basis of retrospective, non-randomised studies. We did this randomised trial to assess the effect of adjuvant radiotherapy on lymph-node field control in patients who had undergone therapeutic lymphadenectomy for metastatic melanoma in regional lymph nodes. METHODS: This randomised controlled trial included patients from 16 hospitals in Australia, New Zealand, the Netherlands, and Brazil. To be eligible for this trial, patients had to be at high risk of lymph-node field relapse, judged on the basis of number of nodes involved, extranodal spread, and maximum size of involved nodes. After lymphadenectomy, randomisation was done centrally by computer and patients assigned by telephone in a ratio of 1:1 to receive adjuvant radiotherapy of 48 Gy in 20 fractions or observation, with institution, lymph-node field, number of involved nodes, maximum node diameter, and extent of extranodal spread as minimisation factors. Participants, those giving treatment, and those assessing outcomes were not masked to treatment allocation. The primary endpoint was lymph-node field relapse (as a first relapse)...

Corpuskarzinom im FIGO-Stadium IA und IB: Therapieergebnisse nach Operation und adjuvanter Strahlentherapie bei Patientinnen mit Risikofaktoren; FIGO stage I and II carcinoma of the corpus uteri: therapeutic results after surgical treatment and adjuvant radiotherapy in patients with risk factors

Angerbauer, Katharina
Fonte: Universidade de Tubinga Publicador: Universidade de Tubinga
Tipo: Dissertação
DE_DE
Relevância na Pesquisa
36.769104%
Zielsetzung: Obwohl der positive Effekt adjuvanter Strahlentherapie bei Endometriumkarzinomen mehrfach in Studien nachgewiesen werden konnte, liegen noch immer keine einheitlichen Standardtherapien vor. In dieser Studie wurden Toxizität der adjuvanten Strahlentherapie und Outcome nach adjuvanter Therapie bei Patientinnen mit Endometriumkarzinom im FIGO-Stadium IA und IB mit Risikofaktoren untersucht. Material und Methoden: Die vorliegende Arbeit basiert auf retrospektiv erhobenen Daten von 176 Patientinnen, die in den Jahren 1990-2004 adjuvant nach Endometriumkarzinom in der Universitätsklinik für Strahlentherapie in Tübingen bestrahlt wurden. Es wurden nur Patientinnen in die Studie aufgenommen, bei denen mindestens einer der folgenden Risikofaktoren vorlag: Alter >60 Jahre, Grading G3, klarzellige Histologie oder Lymphangiosis carcinomatosa. Die Patientinnen erhielten eine Hysterektomie und wurden danach adjuvant bestrahlt. 167 Patientinnen wurden intravaginal nach der Afterloading-Methode bestrahlt, 6 Patientinnen wurden extern am Becken und 3 Patientinnen mit einer Kombination aus beiden Bestrahlungsarten bestrahlt. Ergebnisse: Akute Nebenwirkungen der Bestrahlung traten unter externer Beckenbestrahlung und kombinierter Strahlentherapie relativ betrachtet häufiger und stärker auf als unter AL-Therapie. Insgesamt betrachtet kam es aber nur zu milden akuten Nebenwirkungen der Bestrahlung...

Adjuvant radiotherapy versus observation alone, after radical prostatectomy in high risk prostate cancer

Petruzziello,Andrea; Kato,Massakazu; Nienkotter,Lais Cristine; Souza,Luis Felipe Matiusso de; Dias,Luiz Antônio Negrão; Luz,Murilo
Fonte: Associação Médica Brasileira Publicador: Associação Médica Brasileira
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/08/2015 EN
Relevância na Pesquisa
36.67082%
SummaryObjectives:the authors compared biochemical and clinical outcomes of patients with resected high-risk prostate cancer, managed with adjuvant radiotherapy or observation alone.Methods:patients treated with radical prostatectomy (RP) between January 1995 and December 2005 at the authors’ department were evaluated. Patients with pT3, with or without positive surgical margins (PSM), were included for analysis. Demographic, clinical, pathologic and follow-up data were recorded. Comparison was made between adjuvant radiotherapy group (AR) and observation alone group (OA). Primary end-point was biochemical progression-free survival.Results:out of 739 patients treated with RP, 49 presented with pT3 with or without PSM. 39 received adjuvant radiotherapy and 10 were observed. Median follow- up was 6.2 years for AR and 7.3 years for OA. Biochemical progression occurred in 12.8%, in AR, and 70%, in OA (p=0.0008). Five-year biochemical progression-free survival was 87.1% in AR and 30% in OA (HR 0.12, 95% CI 0.03- 0.48 – p<0.0001). Rescue androgen deprivation therapy was needed in 2.6%, in AR, and 30%, in OA (p=0.023).Conclusions:adjuvant radiotherapy after radical prostatectomy in high-risk prostate cancer provided better biochemical outcomes. Whether this translates into better clinical progression...

An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant; An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT(TM) is functionally superior to Freund's adjuvant

Stevens, N.; Fraser, C.; Alsharifi, M.; Brown, M.; Diener, K.; Hayball, J.
Fonte: Public Library of Science Publicador: Public Library of Science
Tipo: Artigo de Revista Científica
Publicado em //2013 EN
Relevância na Pesquisa
36.790166%
Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age, and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant CoVaccine HT™ was compared to Freund’s adjuvant which is currently the adjuvant of choice for commercial production of ovine polyclonal Fab therapies. CoVaccine HT™ induced significantly higher titres of functional ovine anti-haemagglutinin IgG than Freund’s adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge...

Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: The UK perspective

Karnon, J.; Delea, T.; Johnston, S.; Smith, R.; Brandman, J.; Sung, J.; Goss, P.
Fonte: Adis International Ltd Publicador: Adis International Ltd
Tipo: Artigo de Revista Científica
Publicado em //2006 EN
Relevância na Pesquisa
36.711572%
BACKGROUND: MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrolment) with early breast cancer, post-5 years' adjuvant tamoxifen therapy. The objective of this evaluation was to extrapolate the findings from the MA17 trial to estimate the lifetime cost effectiveness of letrozole in this setting. METHODS: A Markov model was used to estimate the incremental cost per QALY gained with extended adjuvant letrozole versus no therapy. Probabilities of disease progression and death were estimated using data from the MA17 study and other secondary sources. Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature. A full probabilistic sensitivity analysis was undertaken. The analysis was conducted from the perspective of the UK National Health Service (NHS) and cost estimates reflect 2004 values. All costs and outcomes were discounted at 3.5%. RESULTS: Extended adjuvant letrozole resulted in a gain of 0.36 QALYs per patient (13.66 vs 13.30 with no therapy). These benefits were obtained at an additional expected lifetime cost of pound3732 per patient ( pound10 833 letrozole vs pound7101 with no therapy). Cost effectiveness was estimated at pound10 338 per QALY gained (95% CI 5276...

Avaliação da atividade adjuvante da subunidade B recombinante da enterotoxina termolábil de Escherichia coli fusionada ou co-administrada a rFimA de Salmonella Enteritidis; Evaluation of the adjuvant activity of recombinant Escherichia coli heat-labile enterotoxin B subunit fused or co-administered to rFimA of Salmonella Enteritidis.

Sehn, Carla Pohl
Fonte: Universidade Federal de Pelotas; Biotecnologia; Programa de Pós-Graduação em Biotecnologia; UFPel; BR Publicador: Universidade Federal de Pelotas; Biotecnologia; Programa de Pós-Graduação em Biotecnologia; UFPel; BR
Tipo: Dissertação Formato: application/pdf
POR
Relevância na Pesquisa
36.790166%
The association of vaccine antigens to potent immunological adjuvants is a key strategy to improve the performance of subunit vaccines. Adjuvants are components that, when used in combination with a specific antigen, induce more immunity that the antigen alone. Microbial products have been used as adjuvant, including the B subunit of the thermo labile entherotoxin of Escherichia coli (LTB), which is atoxic. LTB is known by its great efficiency as mucosal immunity adjuvant and this activity depends on the shape of the antigen combination (co-administered or fused), on the immunization route (mucosal or parentheral) and the dosage. This study aims to evaluate the adjuvant activity of recombinant LTB (rLTB), both as chimeric and coadministered orally or intramuscularly, using the major fimbrial unit type 1 (FimA) of Salmonella Enteritidis as antigen. BALB/c mice were immunized orally or intramuscularly with three doses of rLTB or PBS (controls) or rFimA, rFimA associated with Freund's incomplete adjuvant (rFimA+AI, i.m. immunized animals), co-administered or fused to LTB (chimera). The levels of total systemic antibodies, IgG1, IgG2a and IgA anti-rFimA were measured by ELISA and an animal protection assay against S. Typhimurium infection was performed. The results show that rLTB only showed adjuvant activity that resembled the commercial adjuvant when coadministered intramuscularly to rFimA and for totals antibody production. These results confirm that the action of adjuvant rLTB is influenced by the shape of binding to the antigen (fused or co-administered) and route of administration. Immunizations did not induce protection of mice challenged with S. Typhimurium...

EVALUATION OF N-RATIO IN SELECTING PATIENTS FOR ADJUVANT CHEMORADIOTHERAPY AFTER D2-GASTRECTOMY

COSTA JUNIOR,Wilson Luiz da; COIMBRA,Felipe José Fernández; BATISTA,Thales Paulo; RIBEIRO,Héber Salvador de Castro; DINIZ,Alessandro Landskron
Fonte: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia - IBEPEGE ; Colégio Brasileiro de Cirurgia Digestiva - CBCD ; Sociedade Brasileira de Motilidade Digestiva - SBMD ; Federação Brasileira de Gastroenterologia - FBG; Sociedade Brasileira de Hepatologia - SBH; Sociedade Brasileira de Endoscopia Digestiva - SOBED Publicador: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia - IBEPEGE ; Colégio Brasileiro de Cirurgia Digestiva - CBCD ; Sociedade Brasileira de Motilidade Digestiva - SBMD ; Federação Brasileira de Gastroenterologia - FBG; Sociedade Brasileira de Hepatologia - SBH; Sociedade Brasileira de Endoscopia Digestiva - SOBED
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/12/2013 EN
Relevância na Pesquisa
36.743467%
ContextWhether adjuvant chemoradiotherapy may contribute to improve survival outcomes after D2-gastrectomy remains controvertial.ObjectiveTo explore the clinical utility of N-Ratio in selecting gastric cancer patients for adjuvant chemoradiotherapy after D2-gastrectomy.MethodsA retrospective cohort study was carried out on gastric cancer patients who underwent D2-gastrectomy alone or D2-gastrectomy plus adjuvant chemoradiotherapy (INT-0116 protocol) at the Hospital A. C. Camargo from September 1998 to December 2008. Statistical analysis were performed using multiple conventional methods, such as c-statistic, adjusted Cox's regression and stratified survival analysis.ResultsOur analysis involved 128 patients. According to c-statistic, the N-Ratio (i.e., as a continuous variable) presented “area under ROC curve” (AUC) of 0.713, while the number of metastatic nodes presented AUC of 0.705. After categorization, the cut-offs provide by Marchet et al. displayed the highest discriminating power – AUC value of 0.702. This N-Ratio categorization was confirmed as an independent predictor of survival using multivariate analyses. There also was a trend of better survival by adding of adjuvant chemoradiotherapy only for patients with milder degrees of lymphatic spread – 5-year survival of 23.1% vs 66.9%...

Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer

Ricci,Marcos Desídérío; Formigoni,Maria Carolina; Zuliani,Lucia Maria Martins; Aoki,Denis Seiiti; Mota,Bruna Salani; Filassi,José Roberto; Piato,José Roberto Morales; Baracat,Edmund Chada
Fonte: Federação Brasileira das Sociedades de Ginecologia e Obstetrícia Publicador: Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/11/2014 EN
Relevância na Pesquisa
36.807773%
PURPOSE: To evaluate variations in the body mass index in patients undergoing adjuvant chemotherapy for breast cancer, and to associate these changes with patient's age and adjuvant chemotherapy regimen. METHODS: We performed a retrospective cohort study in order to correlate any variation in the body mass index before and after adjuvant chemotherapy with patient's age and adjuvant chemotherapy regimen. Patients who received any form of prior hormone therapy, such as tamoxifen or aromatase inhibitors, were excluded. We selected data for 196 patients with stage I to III breast cancer who were treated by radical or conservative surgery and received adjuvant chemotherapy at the Cancer Institute of the State of São Paulo, Brazil. RESULTS: Before adjuvant chemotherapy, 67.8% of patients were classified as overweight or obese according to their body mass indices. Around 66.3% (95% CI 59.7–73.0) of the patients exhibited an increase in the body mass index after adjuvant chemotherapy. The average age of all patients was 56.3±11.3 years. Participants whose body mass index increased were younger than those with no increase (54.7±11.1 versus 59.3±11.2 years; p=0.007). Patients were treated with the following adjuvant chemotherapy regimens: doxorubicin...

Adjuvant treatment of gastric cancer in a long term follow-up

Federico,Miriam Honda; Zilberstein,Bruno; Cecconello,Ivan; Jacob,Carlos Eduardo; Bresciani,Cláudio; Kenji,Osmar; Mucerino,Donato; Lopasso,Fábio
Fonte: Colégio Brasileiro de Cirurgia Digestiva Publicador: Colégio Brasileiro de Cirurgia Digestiva
Tipo: Artigo de Revista Científica Formato: text/html
Publicado em 01/03/2009 EN
Relevância na Pesquisa
36.67082%
BACKGROUND: Advanced gastric cancer carries a poor-prognosis. The best extent of the node dissection and the value of postoperative adjuvant treatments remain open questions. AIM: To study the efficacy of adjuvant chemoradiation and the prognostic value of some clinico-pathological variables in gastric cancer previously submitted to surgery. METHODS: Retrospective single institution study of 69 patients with histological diagnoses of gastric adenocarcinoma, consecutively submitted to radical surgery with curative intent in a five years period. Lymph node dissection was either D1 or D2 at the surgeon's description. All patients were submitted to adjuvant chemoradiation according to MacDonald et al.². Treatment discontinuation and early deaths were considered as serious toxic events. Clinical-pathological variables (the extent D level of the node dissection, T/N-stage, histological subtype, margin status, number of the dissected nodes) were correlated to the results. Overall survival was estimated according to the Kaplan-Meier method and the curves were compared by the log-rank test. RESULTS: Patients characteristics: 48 male/21 female, median age 56,4 y (30-79). In 25 patients, the extent of node dissection was D1, in 41 was D2 and D0 in 3. Staging (n): T2 (16); T3 (49); T4 (4); No (11); N1 (29); N2 (20); N3 (8); Nx (1). Histological subtype: intestinal (45)...

Estudio de la capacidad adyuvante de la proteína Omp19 de Brucella spp. sobre la respuesta inmune adaptativa; Study of the adjuvant capacity of U-Omp19 from Brucella spp. on the adaptive immune responses

Coria, Mirta Lorena
Fonte: Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires Publicador: Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires
Tipo: info:eu-repo/semantics/doctoralThesis; tesis doctoral; info:eu-repo/semantics/publishedVersion Formato: application/pdf
Publicado em //2014 SPA
Relevância na Pesquisa
36.67082%
En nuestro laboratorio nos encontramos investigando la utilidad de la porción proteica de la lipoproteína de membrana externa de 19 kiloDalton de Brucella abortus (U-Omp19) como adyuvante vacunal. Resultados previos proponían a U-Omp19 como un inhibidor de serin proteasas de estómago e intestino. En esta tesis hemos comprobado que U-Omp19 posee actividad de inhibidor de cisteín proteasas lisosomales y que la co-administración de U-Omp19 inhibe parcialmente la degradación del antígeno (Ag) dentro de las células presentadoras de Ag incrementando su vida media y promoviendo su presentación cruzada a las células T CD8+. UOmp19 también es capaz de activar células dendríticas (DCs) induciendo un aumento en la expresión de moléculas co-estimulatorias y secreción de citoquinas pro-inflamatorias. Por último, estudiamos la respuesta inmune inducida en ratones luego de la co-administración de OVA y U-Omp19 por vía subcutánea. Observamos que U-Omp19 como adyuvante de OVA induce una eficiente respuesta inmune celular de tipo T CD8+ y citotóxica con producción de IFN-γ. Los resultados obtenidos indican que la actividad adyuvante de U-Omp19 está dada, por un lado, por su capacidad de activar DCs y por otro lado, por promover la estabilidad y la presentación de Ags a través de su acción como inhibidor de proteasas...

Use of γ-inulin/liposomes/Vitamin E adjuvant combination in contraceptive vaccines

Fuentes, P; Cooper, Peter; Barnadas, R; Sabes, M; Osterhoff, C; Martinez, P
Fonte: Elsevier Publicador: Elsevier
Tipo: Artigo de Revista Científica
Relevância na Pesquisa
36.711572%
The adjuvanticity of two gamma inulin/liposomes/Vitamin E combinations was evaluated in the mouse, in contraceptive vaccines with sperm protein extracts or a synthetic HE2 peptide ("Human Epididymis gene product"; residues 15-28) as antigen. The HE2 peptide was not conjugated to a protein carrier, to ensure that the antibodies elicited were specific against the HE2 peptide. The adjuvant combinations were designed to increase adjuvanticity, as their components have complementary mechanisms, and their performance was compared to Freund's adjuvant. Antibody production against native sperm structures was determined in sera by ELISA immunoassay and immunohistology. Toxicity of adjuvants was determined by histopathological study and treated mice were monitored for signs of pain or distress. Our results show that the gamma inulin (1-2μm particle size)/liposomes/Vitamin E combination, with sperm protein extracts, is better than Freund's adjuvant because it elicits good antibody titres without any toxicity. When the synthetic HE2 peptide is used as antigen, the gamma inulin (1-2μm particle size)/liposomes/Vitamin E combination is less effective than Freund's adjuvant; nevertheless, the anti-HE2 antibodies elicited are highly specific and recognize native structures in sperm.

Evidence Supports Adjuvant Radiotherapy in selected Patients with Rectal Cancer

Gibbs, Peter; Chao, Michael; Jones, Ian T; Yip, Desmond
Fonte: Blackwell Science Asia Publicador: Blackwell Science Asia
Tipo: Artigo de Revista Científica
Relevância na Pesquisa
36.743467%
Background: Much recent data have been published on the risk of local recurrence (LR) following curative surgery for rectal cancer and the impact of adjuvant radiation therapy (RT). With improvements in surgical technique apparently reducing the risk of LR, the relevance of older data upon which the current recommendations for adjuvant RT are based has been questioned. Methods: A focused review was undertaken of the published literature on the risk of LR following surgery for rectal cancer and the impact of adjuvant radiation. In particular the authors attempt to define how accurately the risk for an individual patient can be predicted, trends in reported LR rates over the time period of randomized trials, and the relevance of changing surgical and RT techniques. Results: Many of the perceived differences in published results can be explained by variations in study entry criteria, length of follow up and data recording. Comparisons between studies are most accurate when defined subsets of patients, such as those with stage III disease, followed for the same period of time, are considered. In parallel with improvements in surgical technique, which may have reduced the risk of LR, modifications to RT delivery have resulted in recent series not reporting an increased mortality in those patients treated with modern RT techniques. Conclusion: All of the available evidence supports the use of adjuvant RT in selected patients with rectal cancer. Ongoing studies will better define individual patient risk and the risk-benefit ratio of adjuvant RT.